What pharma executives’ 2026 outlook means for drug spend—and what payers should do now
At this year’s JPMorgan Healthcare Conference, pharmaceutical executives weren’t talking about growth at any cost. They were talking about containment, recovery, and survival.
Across the board, the message was consistent:
• Drug pricing pressure is real
• Patent cliffs are unavoidable
• Dealmaking is back, but it’s defensive
Over the next decade, roughly $300 billion in branded drug revenue will shrink as they hit their patent expiration dates. At the same time, pricing agreements tied to “most-favored-nation” policies are lowering expectations about what manufacturers can charge, particularly in Medicaid and direct-to-consumer channels.
For pharma, the playbook is clear: offset losses with pipeline bets, volume growth, and disciplined M&A. For payers, plan sponsors, and PBMs, the implications are even clearer.
Pricing pressure isn’t theoretical anymore
Pharma executives described recent pricing deals as “manageable,” “modest,” and “low single-digit” impacts to global revenue. That framing matters.
It signals that manufacturers are already absorbing pricing pressure as a baseline assumption, not a shock. In other words, the era of unlimited tolerance for drug spend is over—even from the supply side.
When manufacturers plan for tighter pricing, downstream stakeholders should assume less cushion, less flexibility, and more scrutiny on every dollar flowing through the system.
Patent cliffs create volatility and opportunity
Patent expirations for drugs like Keytruda, Eliquis, Ozempic, and Wegovy will introduce generics, biosimilars, and therapeutic alternatives at scale.
While the transition from brand to generic always creates noise, it also creates avoidable waste when plans fail to move quickly or safely toward the newly available lower-cost equivalents.
This is where strategy really matters.
Plans that react late to market disruptors like regulatory change, biosimilar availability, or point-of-care tools tend to absorb avoidable spending. Plans that utilize innovative pharmacy cost containment solutions can optimize what they already cover and can act earlier, more predictably, and with less operational friction than plans that don’t.
Dealmaking is defensive. Optimization is durable.
Pharma leaders were explicit: acquisitions and partnerships are meant to replace lost revenue, not fuel explosive growth. That same logic applies to pharmacy spend management.
Chasing savings through blunt levers often introduces risk, abrasion, or member disruption. Durable savings come from identifying clinically appropriate, lower-cost alternatives already within coverage and executing those changes in a physician-directed way.
What this means for payers right now
The takeaway from JPMorgan isn’t that prices will suddenly collapse or that innovation will stall. It’s that financial discipline is now embedded into the system’s assumptions.
In that environment:
• Small inefficiencies compound faster
• Missed switch opportunities linger longer
• Avoidable spend becomes harder to justify
Where RazorMetrics fits in this moment
As drug pricing tightens and patent-driven volatility accelerates, plans don’t need more disruption. They need earlier signal, cleaner execution, and savings they can stand behind.
RazorMetrics helps payers, PBMs, and plan sponsors optimize pharmacy spend that is already approved and already covered by:
- Identifying lower-cost therapeutic alternatives early, before abandonment, non-adherence, or downstream medical spend takes hold
- Executing changes in a physician-directed way, preserving clinical autonomy and avoiding workflow disruption
- Capturing savings from generics, biosimilars, deprescribing, and therapeutic optimization as patent cliffs and pricing shifts unfold
- Delivering durable ROI without changing benefits, restricting access, or waiting on regulatory change
In an environment where manufacturers are planning for tighter margins and investors are rewarding discipline, pharmacy strategy has to move upstream. As the industry recalibrates expectations for 2026, the winning strategy looks like quiet precision, applied early, and at scale.
RazorMetrics helps plans do exactly that—quietly, safely, and at scale—so tightening budgets translate into smarter spend, not deferred care or member friction. Get in touch with us today to see what we can do for you.
